This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castilla, C. Articles by Sáez, C. Search for Related Content PubMed PubMed Citation Articles by Castilla, C. Articles by Sáez, C.

Bcl-xL Is Overexpressed in Hormone-Resistant Prostate Cancer and Promotes Survival of LNCaP Cells via Interaction with Proapoptotic Bak

Departments of Pathology (C.C., D.C., M.A.J., C.S.) and Urology (B.C., F.J.T.), Hospitales Universitarios Virgen del Rocío, Seville 41013, Spain

Address all correspondence and requests for reprints to: Carmen Sáez, M.D., Department of Pathology, Hospitales Universitarios Virgen del Rocío, Avenida Manuel Siurot s/n, Seville 41013, Spain. E-mail: csaez{at}cica.es.

Androgen-sensitive prostate cancer cells turn androgen resistant through complex mechanisms that involve dysregulation of apoptosis. We investigated the role of antiapoptotic Bcl-xL in the progression of prostate cancer as well as the interactions of Bcl-xL with proapoptotic Bax and Bak in androgen-dependent and -independent prostate cancer cells. Immunohistochemical analysis was used to study the expression of Bcl-xL in a series of 139 prostate carcinomas and its association with Gleason grade and time to hormone resistance. Expression of Bcl-xL was more abundant in prostate carcinomas of higher Gleason grades and significantly associated with the onset of hormone-refractory disease. In vivo interactions of Bcl-xL with Bax or Bak in untreated and camptothecin-treated LNCaP and PC3 cells were investigated by means of coimmunoprecipitation. In the absence of any stimuli, Bcl-xL interacts with Bax and Bak in androgen-independent PC3 cells but only with Bak in androgen-dependent LNCaP cells. Interactions of Bcl-xL with Bax and Bak were also evidenced in lysates from high-grade prostate cancer tissues. In LNCaP cells treated with camptothecin, an inhibitor of topoisomerase I, the interaction between Bcl-xL and Bak was absent after 36 h, Bcl-xL decreased gradually and Bak increased coincidentally with the progress of apoptosis. These results support a model in which Bcl-xL would exert an inhibitory effect over Bak via heterodimerization. We propose that these interactions may provide mechanisms for suppressing the activity of proapoptotic Bax and Bak in prostate cancer cells and that Bcl-xL expression contributes to androgen resistance and progression of prostate cancer.

This article has been cited by other articles:

				T. Revil, J. Pelletier, J. Toutant, A. Cloutier, and B. Chabot Heterogeneous Nuclear Ribonucleoprotein K Represses the Production of Pro-apoptotic Bcl-xS Splice Isoform J. Biol. Chem., August 7, 2009; 284(32): 21458 - 21467. [Abstract] [Full Text] [PDF]

				L. Wang, D. T. Sloper, S. N. Addo, D. Tian, J. W. Slaton, and C. Xing WL-276, an Antagonist against Bcl-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth Cancer Res., June 1, 2008; 68(11): 4377 - 4383. [Abstract] [Full Text] [PDF]

				H. Hu, G.-x. Li, L. Wang, J. Watts, G. F. Combs Jr., and J. Lu Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin Clin. Cancer Res., February 15, 2008; 14(4): 1150 - 1158. [Abstract] [Full Text] [PDF]

				X.-B. Shi, L. Xue, J. Yang, A.-H. Ma, J. Zhao, M. Xu, C. G. Tepper, C. P. Evans, H.-J. Kung, and R. W. deVere White An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells PNAS, December 11, 2007; 104(50): 19983 - 19988. [Abstract] [Full Text] [PDF]

				J. Witham, M. R. Valenti, A. K. De-Haven-Brandon, S. Vidot, S. A. Eccles, S. B. Kaye, and A. Richardson The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin Clin. Cancer Res., December 1, 2007; 13(23): 7191 - 7198. [Abstract] [Full Text] [PDF]

				S. Giorgini, D. Trisciuoglio, C. Gabellini, M. Desideri, L. Castellini, C. Colarossi, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression Mol. Cancer Res., August 1, 2007; 5(8): 761 - 771. [Abstract] [Full Text] [PDF]